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Background: Brimonidine is a highly selective α2 adrenergic agonist that has been widely used in anti-glaucoma eyedrops.
The aim of this study was to investigate its putative anti-fibrotic role in the fibrosis caused by activated Tenon’s fibroblasts.
Methods: Primary cultured human Tenon’s fibroblasts were exposed to 2.0 ng/mL of transforming growth factor-β1
(TGF-β1) for up to 48 h. In the presence of various concentrations of brimonidine (from 0.0 to 10.0 μM), the expression
levels of fibronectin, collagen types I and III, and β-actin were determined by Western immunoblots. The expression of
phosphorylated SMAD2/3 (p-SMAD2/3) was then evaluated using immunofluorescence.
Results: TGF-β1 significantly increased the synthesis of fibronectin and collagens in human Tenon’s fibroblasts;
however brimonidine treatment distinctly attenuated the TGF-β1-induced production of extracellular matrix (ECM)
proteins. TGF-β1 also changed the cellular morphology to be plump, while brimonidine treatment returned the cells
to a spindle shape, similar to control fibroblasts. Regarding p-SMAD2/3, brimonidine treatment did not show any
apparent changes in its expression.
Conclusions: Our data revealed that brimonidine reduces TGF-β-induced ECM synthesis in human Tenon’s fibroblasts
in vitro. This finding implies that topical administration of brimonidine may be helpful in reducing the fibrosis caused
by the long-term use of topical anti-glaucoma medications.
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Excessive subconjunctival fibrosis causes failure after
glaucoma filtering surgery and transforming growth
factor-β (TGF-β) is known to play a crucial role in this
pathologic process. Though many anti-glaucoma eye-
drops have been reported to induce conjunctival and/or
subconjunctival fibrosis [1–3], information about the
effects of brimonidine in this process remains scarce.
Brimonidine is a highly selective α2 adrenergic agonist
that has been widely used as an anti-glaucoma ophthalmic
solution [4–7]. It reduces intraocular pressure (IOP) by
decreasing production of aqueous humor and increasing
uveoscleral outflow. Several in vivo as well as in vitro stud-
ies have reported that brimonidine may directly protect
retinal ganglion cells and optic nerve fibers in addition to
lowering IOP; however a definite conclusion has not been* Correspondence: gjseong@yuhs.ac
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Some previous reports dealt with the adverse effects of
perioperative use of brimonidine for laser in situ kerato-
mileusis (LASIK) [8–10]. Topical administration of bri-
monidine was found to raise the incidence of corneal
flap dislocation after LASIK and Walter and Gilbert [8]
suggested the following possible mechanisms: (1) brimo-
nidine itself or brimonidine-containing eyedrops may act
as a lubricant and cause the flap to slide from the cor-
neal bed, (2) brimonidine may cause vasoconstriction of
the anterior ocular vessels and decrease the corneal
endothelial function to maintain proper flap adherence,
and (3) brimonidine itself may be directly toxic to the
corneal endothelial cells and reduce their metabolic activ-
ity. However, the precise mechanisms of this phenomenon
have not yet been proven.
We hypothesized that brimonidine disturbs the healing/
fibrotic process after LASIK surgery. Given than cornealticle distributed under the terms of the Creative Commons Attribution License
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fibroblasts, in the present study we attempted to assess
whether brimonidine reduces TGF-β-induced extracellular
matrix (ECM) synthesis in primary cultured human Tenon’s
fibroblasts.Methods
Cell culture and exposure to TGF-β1
Our protocol was approved by the Institutional Review
Board of Gangnam Severance Hospital, Yonsei University
College of Medicine, and all experiments were performed
in compliance with the tenets of the Declaration of
Helsinki. Subjects who had no ocular/systemic disease ex-
cept for horizontal strabismus received comprehensive in-
formation and provided written informed consent. Patients
with previous ocular surgery and/or trauma history were
not included in the study.
Small Tenon’s capsule specimens were excised during
strabismus surgeries and fibroblasts were isolated as previ-
ously described [11–13]. Cells were incubated in Dulbecco’s
modified Eagle’s medium (DMEM; Life Technologies,
Carlsbad, CA) supplemented with 10 % fetal bovine serum
(FBS; Life Technologies), 100 units/mL penicillin (Life
Technologies), and 100 μg/mL streptomycin (Life Tech-
nologies) at 37 °C and 5 % CO2. We used cells between the
third and fifth passages for this study, and cultures were
allowed to reach about 80 % confluence.
After 24 h of serum deprivation in serum-free DMEM,
the fibroblasts were exposed to 2.0 ng/mL recombinant
human TGF-β1 (R&D Systems, Minneapolis, MN) for
up to 48 h. In the brimonidine treatment group, the cells
were treated with various concentrations of brimonidine
(Sigma-Aldrich, St. Louis, MO). All experiments were
performed in at least quadruplicate and were repeated at
least four times using independent cell cultures.Western immunoblots
Whole cellular proteins were extracted from primary
cultured human Tenon’s fibroblasts. Briefly, total cell lysates
were obtained using cell lysis buffer (Sigma-Aldrich) on ice
for 10 min. The lysates were sonicated and the cell homog-
enates were centrifuged at 15,000 g for 10 min at 4 °C.
Protein concentrations in the resultant supernatants
were determined with the Bio-Rad Protein Assay (Bio-
Rad Laboratories, Hercules, CA) based on the Bradford
dye-binding procedure. Equal amounts of protein
(10 μg) were boiled in Laemmli sample buffer and re-
solved by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE). The proteins were trans-
ferred to polyvinylidene fluoride (PVDF) membranes
and probed overnight with primary antibodies against
human fibronectin, collagen types I and III, and β-actin
(diluted 1:500; Santa Cruz Biotechnology, Dallas, TX).Immunoreactive bands were detected with horseradish
peroxidase-conjugated secondary antibodies (diluted
1:2,000; Santa Cruz Biotechnology) and visualized by an
enhanced chemiluminescent system (SuperSignal West
Pico Chemiluminescent Substrates, Pierce Biotechnology,
Rockford, IL) on autoradiograph films.
Immunofluorescence
The cells were fixed with 4 % paraformaldehyde for
30 min, treated with 0.1 % Triton X-100 in 0.1 % Na-Cit-
rate for 10 min, and then blocked with 2 % bovine serum
albumin (Sigma-Aldrich) for an hour. They were incu-
bated with anti-human SMAD2/3 and phosphorylated
SMAD2/3 (p-SMAD2/3) antibodies (1:50 dilution; Santa
Cruz Biotechnology) overnight at 4 °C and then exposed
to the Alexa Fluor® 594-conjugated and fluorescein isothio-
cyanate (FITC)-conjugated secondary antibodies (1:100 di-
lution; Life Technologies), respectively, for 60 min at room
temperature. Mounting medium containing 4’,6-diamidino-
2-phenylindole (DAPI; Santa Cruz Biotechnology) was ap-
plied and four random fields were imaged under a fluores-
cence microscope. SMAD2/3 was finally noticed with
Alexa Fluor® 594 of red fluorescence, p-SMAD2/3 was la-
beled with FITC of green fluorescence, and all nuclei were
counterstained with DAPI of blue fluorescence.
Statistical analysis
Data are expressed as means ± standard error of the
mean (S.E.M.). Data were compared using the Kruskal-
Wallis one-way analysis of variance using the MedCalc
program for Windows, version 11.4.2.0 (MedCalc Soft-
ware bvba, Mariakerke, Belgium). P-values less than 0.05
were considered statistically significant.
Results
Data from the Western immunoblots are shown in Fig. 1.
When human Tenon’s fibroblasts were exposed to TGF-
β1 for 48 h, the levels of synthesis of fibronectin and col-
lagen types I and III significantly increased. Brimonidine
treatment distinctly attenuated this TGF-β-induced
ECM protein synthesis. The anti-fibrotic effect of brimo-
nidine on fibronectin was notable at a low concentration
(1.0 μM) of brimonidine, while its effect on collagens
was obvious at a high concentration of 10.0 μM.
Representative immunofluorescence pictures are shown
in Fig. 2. Human Tenon’s fibroblasts normally have a spin-
dle shape (Fig. 2a). When the cells were exposed to TGF-
β1 for 24 h, their cellular morphology became plump
(Fig. 2b). Brimonidine treatment returned the cell shape
to something similar to that of unstressed control cells
(Fig. 2c). Furthermore, brimonidine treatment did not
cause any apparent changes in the expression of p-
SMAD2/3.
Fig. 1 a Western immunoblots of primary cultured human Tenon’s fibroblasts. The cells were exposed to TGF-β1 (2.0 ng/mL) for up to 48 h in
the presence of brimonidine. b Band intensity is expressed as ratio to control. Asterisk, p < 0.05
Fig. 2 Representative immunofluorescence of primary cultured human Tenon’s fibroblasts. The cells were exposed to TGF-β1 (2.0 ng/mL) for 24 h
in the presence of 10.0 μM brimonidine. a No treatment control; b TGF-β1 exposure only; c TGF-β1 exposure with brimonidine treatment.
Phosphorylated SMAD2/3 was labeled with green fluorescence of fluorescein isothiocyanate. Scale bar, 200 μm
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In this in vitro study, in order to investigate the
anti-fibrotic effects of brimonidine on activated human
Tenon’s fibroblasts, the primary cultured human Tenon’s
fibroblasts were treated with 2.0 ng/mL of TGF-β1 for
up to 48 h in the presence of various concentrations of
brimonidine. As seen in the results of Western immuno-
blots, TGF-β1 significantly increased the protein synthe-
sis of fibronectin and collagen types I and III compared
to unstressed control cells. However, brimonidine treat-
ment attenuated this TGF-β-induced increase in ECM
protein synthesis.
Leng et al. [3] reported that human Tenon’s fibroblasts
isolated from glaucoma patients with long-term use of
topical anti-glaucoma eyedrops were highly proliferative
and had elevated TGF-β expression compared to cells
isolated from control subjects. Several earlier studies
also demonstrated that the anti-glaucoma medications
changed the expression levels of matrix metalloprotein-
ases (MMPs) and tissue inhibitors of metalloproteinases
(TIMPs), as well as the synthesis of interleukin (IL)-6 in
Tenon’s fibroblasts cultured from glaucoma patients
[14–16]. Though IL-6 is an essential chemoattractant
and stimulator of lymphocytes [17], it participates in the
core fibrotic process of transdifferentiation from Tenon’s
capsule fibroblasts to myofibroblasts [11, 15]. Thus, all
previous studies have produced a common idea that top-
ical anti-glaucoma eyedrops may affect the fibrosis in
glaucoma patients and influence the success of glaucoma
filtering surgery. However, the previous studies are
mainly regarding prostaglandin analogues rather than
brimonidine. That is why we investigated the putative
anti-fibrotic effect of brimonidine on human Tenon’s
fibroblasts.
While it is not clear how brimonidine suppresses the
TGF-β-induced ECM production in the cells, according
to our immunofluorescence results, brimonidine does
not seem to influence the activity of SMAD2/3, which
are the receptor-regulated transcription factors that initi-
ate the intracellular TGF-β signaling. Alpha adrenergic
system is involved in tissue fibrosis and remodeling via
modulation of the TGF-β signaling pathway [18]. Brimoni-
dine may play its anti-fibrotic role via similar molecular
cross-talk. To confirm the anti-fibrotic effects of brimoni-
dine and to determine its precise mechanism, further
in vivo as well as in vitro experiments are needed and are
currently underway. In the future, the effects of brimoni-
dine could also be confirmed by a human clinical trial.
While it is not clear how brimonidine suppresses the
TGF-β-induced ECM production in the cells, according to
our immunofluorescence results, brimonidine does not
seem to influence the activity of SMAD2/3, which are the
receptor-regulated transcription factors that initiate the
intracellular TGF-β signaling. It also does not have anysignificant effect on TGF-β-induced transdifferentiation of
Tenon’s fibroblasts to myofibroblasts (Additional file 1).
Alpha adrenergic system is involved in tissue fibrosis and
remodeling via modulation of the TGF-β signaling path-
way [18]. Brimonidine may play its anti-fibrotic role via
similar molecular cross-talk. To confirm the anti-fibrotic
effects of brimonidine and to determine its precise mech-
anism, further in vivo as well as in vitro experiments are
needed and are currently underway. In the future, the ef-
fects of brimonidine could also be confirmed by a human
clinical trial.
Conclusion
Our data revealed that brimonidine reduces TGF-β1-
induced ECM synthesis in human Tenon’s fibroblasts
in vitro. These findings imply that brimonidine may be
helpful in attenuating the fibrosis caused by the long-term
use of topical anti-glaucoma medications.
Additional file
Additional file 1: Representative Western immunoblots of primary cultured
Tenon’s fibroblasts. The cells were exposed to TGF-β1 (2.0 ng/mL) for up to 48
hours in the presence of brimonidine. αSMA , α smooth muscle actin.
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